Characteristics associated with overall survival in all 54 patients with BCL2+/MYC+ lymphomas
| Variable . | n (%) . | Median OS, y . | P, log-rank . |
|---|---|---|---|
| Age > 60 y at diagnosis | 28 (52) | 0.58 | .003 |
| Male sex | 32 (59) | 0.32 | .825 |
| Performance status > 1 | 19 (35) | 0.27 | .001 |
| Stage > 2 | 41 (76) | 0.30 | .065 |
| LDH > normal | 27 (50) | 0.35 | .923 |
| Extranodal sites > 1 | 19 (35) | 0.18 | < .001 |
| IPI | |||
| 0-1 | 16 (30) | 1.35 | < .001 |
| 2-3 | 24 (44) | 0.48 | |
| 4-5 | 14 (26) | 0.15 | |
| Age at MYC+ > 60 y | 32 (59) | 0.26 | .005 |
| Antecedent MYC− lymphoma | 0.41 | .530 | |
| FL | 19 (35) | ||
| CLL | 1 (2) | ||
| DLBCL | 3 (6) | ||
| Histology with MYC+ | < .001 | ||
| DLBCL | 17 (31) | 2.86 | |
| BCLU | 36 (67) | 0.26 | |
| FL | 1 (2) | ||
| Bone marrow with MYC+ | .001 | ||
| Positive | 32 (59) | 0.20 | |
| Negative | 13 (24) | 1.40 | |
| Not available | 9 (17) | ||
| BCL2 protein expression | .009 | ||
| Positive | 23 (43) | 0.48 | |
| Negative | 5 (9) | 5.66 | |
| Not available | 27 (48) | ||
| CD10 expression | .316 | ||
| Positive | 34 (63) | 0.30 | |
| Negative | 9 (17) | 0.20 | |
| Not available | 11 (20) | ||
| IG/MYC | 30 (56) | 0.26 | .017 |
| Non-IG/MYC | 24 (44) | 0.58 | |
| Treatment | |||
| HD chemo | 6 (11) | 0.26 | < .001 |
| R-CHOP | 11 (20) | 1.40 | |
| CHOP-like | 23 (43) | 0.42 | |
| Palliative | 14 (26) | 0.07 |
| Variable . | n (%) . | Median OS, y . | P, log-rank . |
|---|---|---|---|
| Age > 60 y at diagnosis | 28 (52) | 0.58 | .003 |
| Male sex | 32 (59) | 0.32 | .825 |
| Performance status > 1 | 19 (35) | 0.27 | .001 |
| Stage > 2 | 41 (76) | 0.30 | .065 |
| LDH > normal | 27 (50) | 0.35 | .923 |
| Extranodal sites > 1 | 19 (35) | 0.18 | < .001 |
| IPI | |||
| 0-1 | 16 (30) | 1.35 | < .001 |
| 2-3 | 24 (44) | 0.48 | |
| 4-5 | 14 (26) | 0.15 | |
| Age at MYC+ > 60 y | 32 (59) | 0.26 | .005 |
| Antecedent MYC− lymphoma | 0.41 | .530 | |
| FL | 19 (35) | ||
| CLL | 1 (2) | ||
| DLBCL | 3 (6) | ||
| Histology with MYC+ | < .001 | ||
| DLBCL | 17 (31) | 2.86 | |
| BCLU | 36 (67) | 0.26 | |
| FL | 1 (2) | ||
| Bone marrow with MYC+ | .001 | ||
| Positive | 32 (59) | 0.20 | |
| Negative | 13 (24) | 1.40 | |
| Not available | 9 (17) | ||
| BCL2 protein expression | .009 | ||
| Positive | 23 (43) | 0.48 | |
| Negative | 5 (9) | 5.66 | |
| Not available | 27 (48) | ||
| CD10 expression | .316 | ||
| Positive | 34 (63) | 0.30 | |
| Negative | 9 (17) | 0.20 | |
| Not available | 11 (20) | ||
| IG/MYC | 30 (56) | 0.26 | .017 |
| Non-IG/MYC | 24 (44) | 0.58 | |
| Treatment | |||
| HD chemo | 6 (11) | 0.26 | < .001 |
| R-CHOP | 11 (20) | 1.40 | |
| CHOP-like | 23 (43) | 0.42 | |
| Palliative | 14 (26) | 0.07 |
LDH indicates lactate dehydrogenase; IPI, International Prognostic Index; FL, follicular lymphoma; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; BCLU, B-cell lymphoma, unclassifiable, with features intermediate between Burkitt lymphoma and DLBCL; IG, immunoglobulin; HD chemo, high-dose chemotherapy with or without stem cell transplantation; and R-CHOP, rituximab and CHOP chemotherapy.